Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity. Issue 5 (13th May 2021)

• Record Type: Journal Article
• Authors: Torres, María José; Trautmann, Axel; Böhm, Ingrid; Scherer, Kathrin; Barbaud, Annick; Bavbek, Sevim; Bonadonna, Patrizia; Cernadas, Josefina Rodrigues; Chiriac, Anca Mirela; Gaeta, Francesco; Gimenez‐Arnau, Ana M.; Kang, Hye‐Ryun; Moreno, Esther; Brockow, Knut
• Is Part Of: Allergy. Volume 76:Issue 5(2021)
• Page Start: 1325
• Page End: 1339
• Publication Date: 2021-05-13
• Subjects: Iodinated contrast media -- hypersensitivity -- allergy -- IgE -- T cells -- diagnosis -- management; Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.14656
• Languages: English
• ISSNs: 0105-4538

Abstract

Abstract: Immediate and nonimmediate hypersensitivity reactions to iodinated contrast media (ICM) have been reported to occur in a frequency of about 0.5%‐3% of patients receiving nonionic ICM. The diagnosis and management of these patients vary among guidelines published by various national and international scientific societies, with recommendations ranging from avoidance or premedication to drug provocation test. This position paper aims to give recommendations for the management of patients with ICM hypersensitivity reactions and analyze controversies in this area. Skin tests are recommended as the initial step for diagnosing patients with immediate and nonimmediate hypersensitivity reactions; besides, they may also help guide on tolerability of alternatives. Re‐exposition or drug provocation test should only be done with skin test‐negative ICMs. The decision for performing either re‐exposition or drug provocation test needs to be taken based on a risk‐benefit analysis. The role of in vitro tests for diagnosis and pretreatment for preventing reactions remains controversial.